[HTML][HTML] Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic …

SM Palmer, L Snyder, JL Todd, B Soule, R Christian… - Chest, 2018 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The
lysophosphatidic acid receptor 1 (LPA 1) pathway is implicated in IPF etiology. Safety and
efficacy of BMS-986020, a high-affinity LPA 1 antagonist, was assessed vs placebo in a
phase 2 study in patients with IPF. Methods IM136003 was a phase 2, parallel-arm,
multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-
90%; diffusing capacity for carbon monoxide, 30%-80%) were randomized to receive …